Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02306993 · ClinicalTrials.gov registry record
Sickle Cell Hemoglobinopathies and Bone Health
A clinical trial of Sickle Cell Disease and Sickle Cell Trait, sponsored by UConn Health.
- Active
- Registry status
- 45
- Enrollment target
- 1
- Study location
NCT02306993: Active study of Sickle Cell Disease and Sickle Cell Trait, sponsored by UConn Health.
NCT02306993 is a study of Sickle Cell Disease and Sickle Cell Trait that is active but no longer recruiting, run by UConn Health. The registered enrollment target is 45 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02306993, a study of Sickle Cell Disease and Sickle Cell Trait, is active but no longer recruiting, sponsored by UConn Health.
- ACTIVE NOT RECRUITING
- Registry status
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study has two purposes. The first purpose is to determine whether having sickle cell trait (SCT) is a risk factor for the development of bone thinning at an earlier age than expected. Nearly 10% of African Americans (AA) carry sickle cell trait and most of them are unaware of it. African Americans are less likely to develop thin bones than whites, but if they sustain a bone fracture, they are more likely to die from it. We believe having sickle cell trait may lead to bone thinning and predispose a subset of African Americans to dangerously thin bones. The second purpose is to try to understand why individuals with sickle cell disease (SCD) have thinner bones than healthy individuals do. Doctors have already discovered that people with sickle cell disease have very thin bones, but they have not determined why. Our study will try to identify whether the bone thinning is from the body not making enough bone or from the body losing bone once it is made.
Primary Outcome
Assess the association of hemoglobin genotype with serum bone turnover markers and bone density.
Conditions Studied
Interventions
- OTHER Healthy volunteers without SCT
- OTHER Healthy volunteers with SCT
- OTHER Volunteers with SCD
Study Locations (1)
Connecticut
- UConn Health - Farmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2014-05 |
| Est. Completion | 2025-12 |
What the registry record for NCT02306993 still lists
NCT02306993 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 3 interventions - of which Healthy volunteers without SCT is the first listed.
NCT02306993 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT02306993 about?
NCT02306993 is a clinical study titled "Sickle Cell Hemoglobinopathies and Bone Health". This research study has two purposes. The first purpose is to determine whether having sickle cell trait (SCT) is a risk factor for the development of bone thinning at an earlier age than expected. Nearly 10% of African Americans (AA) carry sickle cell trait and most of them are unaware of it. Afric...
What is the current status of trial NCT02306993?
This trial is currently active not recruiting. The enrollment target is 45 participants. The study started on 2014-05. Estimated completion is 2025-12.
What conditions does trial NCT02306993 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Sickle Cell Trait.
What interventions are being tested in trial NCT02306993?
The interventions under investigation include: Healthy volunteers without SCT (OTHER), Healthy volunteers with SCT (OTHER), Volunteers with SCD (OTHER).
Who is sponsoring clinical trial NCT02306993?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02306993 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02306993's enrollment target sits among peer trials
45 116th of 213 higher than 95 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
-
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
RECRUITING · Phase 1
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia